Open AccessBurkitt Lymphoma in Elderly Patients
Author(s) -
Ivan Petković,
D. Mihailović,
Miljan Krstić,
Ivica Pejčić,
Svetislav Vrbić,
M. Balic
Publication year - 2013
Publication title -
acta facultatis medicae naissensis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.151
H-Index - 8
eISSN - 2217-2521
pISSN - 0351-6083
DOI - 10.2478/v10283-012-0044-0
Subject(s) - medicine , rituximab , lymphoma , chop , disease , population , pediatrics , oncology , environmental health
SUMMARY Burkitt lymphoma (BL) is a disease of predominantly young population, while in the elderly it occurs as a rare neoplasm. Elderly patients (age >60 years) represent a significant problem because of the inability to apply effective aggressive chemiotherapy in these cases. The risk of induction death is very high and unacceptible. Mainly, palliative treatments are applied, whose goal is not curing but maintaining the quality of life. We present the case of a person 75 years old with a diagnosis of sporadic, typical BL treated with CHOP+R in the induction therapy with excellent response but rapid progression after the abolition of rituximab. In discussion, the authors are looking for relevant data on the therapeutic approach in BL in the elderly.